-
In 2022
10.4 billion11
R&D investment reached
(RMB)
-
1771
授权发明专利
-
10 +
Global technology innovation centers
-
- Leading Core technologies in various fields
Innovative drug:focus on therapeutic areas such as oncology,immunology, central nervous system, and chronic disease, and mainly strengthencore technology platforms such as small molecule, antibody/ADC, cell therapy,and RNA
Vaccine: platforms of bacterial vaccine + viral vaccine
Device: three major platforms of medical cosmetology +respiratory health + professional medical care
Research & application of OrientalLifestyle Aesthetics
Construction of the 4D technology innovation system: five senses ofconsumers + technology innovation R&D + creative design + technologyinnovation digitalization
Insurance: digital platformoptimizes customer experience throughout the life cycle
Intelligent travel: full-stack self-developed L2+ intelligentdriving software and hardware solutions
Industrial automation: leveraging digital twin, machine vision andother technologies accumulated for many years in the industry, AIGC largemodels are introduced to promote full intelligence and automation in theindustry
New energy: from traditional energy to the upstreamextension of new energy and new materials
-
- Technology innovation centers in various fields
Fosun Pharma Global R&D Center (national level)
JEVE Technology Center (national level)
Wanbang Biopharma Quality Department QC Lab2 (CNAScertified)
Fosun Cosmetics Global Innovation Center2
Fosun Pharma North America R&D Headquarters
Shanghai Key Laboratory of Stem Cell Therapy
Sichuan Engineering Technology Center for IntelligentBrewing of Baijiu
Lanvin Fabric Innovation Center
Yuyuan Jewelry Designer Center
Yuyuan Foods & Dining Group Innovation Center
Academician Enterprise Research Institute
Fosun Wine & Spirits Group Innovation Center
……
1 It includes scientific research investment (expensed and capitalized), but excludes digitalization expenses.
2 Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress
-
13价肺炎球菌结合疫苗
于中国境内(不包括港澳台地区)处于III期临床阶段
-
HANSIZHUANG (serplulimab injection)
Self-developed biopharmaceutical innovative drug and the world's first monoclonal antibody drug targeting PD-1 for first-line treatment of extensive-stage small cell lung cancer
Approved for three indications in China (excluding Hong Kong, Macau and Taiwan regions) -
Yi Kai Da (ejilunsai injection)
国内第1个获批上市的CAR-T细胞治疗产品
用于二线治疗成人大B细胞淋巴瘤的上市注册申请于中国境内(不包括港澳台地区)获受理并纳入优先审评 -
愈感
第一个自主研发的面向敏感肌护肤品品牌-愈感问世
-
舍得酒业
攻关“保持基酒老酒特征的特制新材料升级处理基酒”技术方案
-
葡萄牙保险
My Fidelidade APP注册用户数突破100万,APP端就诊报销占比>46%,车险数字化理赔占比>48%
-
复睿智行
发布高性能4D毫米波雷达为核心的融合感知方案
-
翌耀科技
自主研发的新能源系统装备首次交付海外大客户
-
海南矿业
投资建设的2万吨氢氧化锂项目(一期)已正式动工,并正在积极推进非洲马里Bougouni锂矿的并购和开发